Axsome Therapeutics, Inc. (FRA:19X)
Germany flag Germany · Delayed Price · Currency is EUR
157.60
-2.95 (-1.84%)
Last updated: Jan 23, 2026, 8:05 AM CET

Axsome Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
561.26385.69270.650.04--
Revenue Growth (YoY)
65.83%42.53%440.80%---
Cost of Revenue
45.6633.326.074.1--
Gross Profit
515.6352.39244.5445.94--
Selling, General & Admin
514.57411.36323.12159.2566.6528.9
Research & Development
189.49187.0897.9457.9558.0670.19
Amortization of Goodwill & Intangibles
6.386.396.384.14--
Operating Expenses
710.44604.83427.44221.34124.7199.09
Operating Income
-194.84-252.44-182.91-175.4-124.71-99.09
Interest Expense
-7.6-6.57-6.45-7.34-5.7-2.57
EBT Excluding Unusual Items
-202.44-259.01-189.36-182.74-130.4-101.65
Merger & Restructuring Charges
----1.1--
Other Unusual Items
-27.97-28.12-48.92-3.3--1.25
Pretax Income
-230.4-287.13-238.28-187.13-130.4-102.9
Income Tax Expense
-0.880.090.96---
Net Income
-229.53-287.22-239.24-187.13-130.4-102.9
Net Income to Common
-229.53-287.22-239.24-187.13-130.4-102.9
Shares Outstanding (Basic)
494845413837
Shares Outstanding (Diluted)
494845413837
Shares Change (YoY)
3.38%5.48%11.73%8.07%1.11%9.37%
EPS (Basic)
-4.66-5.99-5.27-4.60-3.47-2.77
EPS (Diluted)
-4.66-5.99-5.27-4.60-3.47-2.77
Free Cash Flow
-101.39-128.68-145.66-117.21-108.53-78.5
Free Cash Flow Per Share
-2.06-2.69-3.21-2.88-2.88-2.11
Gross Margin
91.86%91.36%90.37%91.81%--
Operating Margin
-34.72%-65.45%-67.59%-350.54%--
Profit Margin
-40.89%-74.47%-88.41%-373.99%--
Free Cash Flow Margin
-18.07%-33.36%-53.83%-234.25%--
EBITDA
-187.95-245.51-176.07-171-124.63-99.06
EBITDA Margin
-33.49%-63.65%-65.07%---
D&A For EBITDA
6.896.926.834.40.080.02
EBIT
-194.84-252.44-182.91-175.4-124.71-99.09
EBIT Margin
-34.72%-65.45%-67.59%---
Revenue as Reported
561.26385.69270.650.04--
Advertising Expenses
-101.2100.335.3--
Source: S&P Global Market Intelligence. Standard template. Financial Sources.